RT Journal Article
SR Electronic
T1 Prostate-specific membrane antigen is a biomarker for residual disease following neoadjuvant intense androgen deprivation therapy in prostate cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.28.21265614
DO 10.1101/2021.10.28.21265614
A1 John R. Bright
A1 Rosina T. Lis
A1 Anson T. Ku
A1 Nicholas T. Terrigino
A1 Shana Y. Trostel
A1 Nicole V. Carrabba
A1 Stephanie A. Harmon
A1 Baris Turkbey
A1 Scott Wilkinson
A1 Adam G. Sowalsky
YR 2021
UL http://medrxiv.org/content/early/2021/10/29/2021.10.28.21265614.abstract
AB Neoadjuvant intense androgen deprivation therapy can exert a wide range of histologic responses, which in turn are reflected in the final prostatectomy specimen. Accurate identification and measurement of residual tumor volumes are critical for tracking and stratifying patient outcomes. The goal of this current study was to evaluate the ability of antibodies against prostate-specific membrane antigen (PSMA) to detect residual tumor in a cohort of 35 patients treated with androgen deprivation therapy plus enzalutamide for six months prior to radical prostatectomy. Residual carcinoma was detected in 31 patients, and PSMA reacted positively with tumor in all cases. PSMA staining was 95.5% sensitive for tumor, with approximately 81.6% of benign regions showing no reactivity. By contrast, PSMA positively reacted with 72.2% of benign regions in a control cohort of 37 untreated cases, resulting in 27.8% specificity for tumor. PSMA further identified highly dedifferentiated prostate carcinomas including tumors with evidence of neuroendocrine differentiation. We propose that anti-PSMA immunostaining be a standardized marker for identifying residual cancer in the setting of neoadjuvant intense androgen deprivation therapy.Competing Interest StatementR.T.L. performs consulting in an advisory role for Janssen Pharmaceuticals. The remaining authors declare no conflicts of interest.Clinical TrialNCT02430480Funding StatementThis work was supported by the Prostate Cancer Foundation (Young Investigator Award to S.W.), the Department of Defense Prostate Cancer Research Program (W81XWH-19-1-0712 to S.W., W81XWH-16-1-0433 to A.G.S.), and the Intramural Research Program of the NIH, National Cancer Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection and analysis of tissue and demographic data from patients with high-risk localized prostate cancer treated with ADT plus enzalutamide prior to surgery was approved by the National Institutes of Health Institutional Review Board (protocol 15-c-0124). The collection and analysis of tissue and demographic data from patients with localized prostate cancer treated only by surgery was approved by the institutional review boards of Beth Israel Deaconess Medical Center (protocol 2010-P-000254/0) and Dana-Farber/Harvard Cancer Center (protocols 15-008 and 15-492).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article are available in the Database of Genotypes and Phenotypes (dbGaP) and Gene Expression Omnibus (GEO) at https://www.ncbi.nlm.nih.gov/gap/ and https://www.ncbi.nlm.nih.gov/, respectively, and can be accessed with phs001813.v2.p1 (dbGaP), phs001938.v3.p1 (dbGaP), GSE183100 (GEO) and GSE183019 (GEO). https://www.ncbi.nlm.nih.gov/gap/ https://www.ncbi.nlm.nih.gov/geo/